Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Intra-lesional chemotherapy for treatment of cutaneous malignancies has been used for many decades, allowing higher local drug concentrations and less toxicity than systemic agents. Here we describe a novel diterpene ester, EBC-46, and provide preclinical data supporting its use as an intra-lesional treatment. A single injection of EBC-46 caused rapid inflammation and influx of blood, followed by eschar formation and rapid tumor ablation in a range of syngeneic and xenograft models. EBC-46 induced oxidative burst from purified human polymorphonuclear cells, which was prevented by the Protein Kinase C inhibitor bisindolylmaleimide-1. EBC-46 activated a more specific subset of PKC isoforms (PKC-βI, -βII, -α and -γ) compared to the structurally related phorbol 12-myristate 13-acetate (PMA). Although EBC-46 showed threefold less potency for inhibiting cell growth than PMA in vitro, it was more effective for cure of tumors in vivo. No viable tumor cells were evident four hours after injection by ex vivo culture. Pharmacokinetic profiles from treated mice indicated that EBC-46 was retained preferentially within the tumor, and resulted in significantly greater local responses (erythema, oedema) following intra-lesional injection compared with injection into normal skin. The efficacy of EBC-46 was reduced by co-injection with bisindolylmaleimide-1. Loss of vascular integrity following treatment was demonstrated by an increased permeability of endothelial cell monolayers in vitro and by CD31 immunostaining of treated tumors in vivo. Our results demonstrate that a single intra-lesional injection of EBC-46 causes PKC-dependent hemorrhagic necrosis, rapid tumor cell death and ultimate cure of solid tumors in pre-clinical models of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Epoxytiglianes, another class of PKC activators, showed efficacy in preclinical mouse models and clinical mast cell tumors in canine models [126, 127, 128].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [126]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766 · cited 2×
“Serial 3-fold dilutions of the cell suspension were cultured in vitro for 6 days, and the SRB assay used to compare the growth of viable EBC-46-treated tumor cells with that of vehicle treated controls.”
MethodNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“This specificity may reflect the disorganization and inherent ‘‘leakiness’’ of the vasculature within a solid tumor [32].”
BackgroundIn situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
Chen, T. R. (1977) · Experimental Cell Research · doi:10.1016/0014-4827(77)90089-1 · Cited by 1,700 · cited 1×
“Cells were routinely checked by STR profiling, and for mycoplasma infection by Hoechst staining [23] and PCR, and were always negative.”
MethodUse of Ly6G-specific monoclonal antibody to deplete neutrophils in mice
Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S., & Albina, J. E. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0407247 · Cited by 1,046 · cited 1×
“Further, the anti-neutrophil antibody used here was from a different, more neutrophil-specific hybridoma clone [33] than that used in previous studies.”
ResultCorbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., & Schabel, F. M. (1975) · PubMed · Cited by 584
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563 · cited 1×
“However, several clinical trials performed with compounds thought to inhibit PKC signaling have had disappointing results [9].”
BackgroundProtein kinase C: poised to signal
Newton, A. C. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2009 · Cited by 512 · cited 1×
“DAG, but have been shown to be activated by distinct lipids and protein-protein interactions [5,6].”
BackgroundRegulation of vascular endothelial barrier function
Lum, H., & Malik, A. B. (1994) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1994.267.3.l223 · Cited by 470 · cited 2×
“Activation of specific PKC isoforms in vascular endothelial cells, particularly the PKC-b isoforms, has previously been shown to induce permeability [30,31].”
BackgroundAntitumor Activity of 3-Ingenyl Angelate
Ogbourne, S. M., Suhrbier, A., Jones, B., Cozzi, S.-J., Boyle, G. M., Morris, M., McAlpine, D., Johns, J., Scott, T. M., Sutherland, K. P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2837 · Cited by 255 · cited 2×
“We have previously demonstrated that three topical applications of the PKC-activating ingenol ester PEP005 (ingenol mebutate or ingenol 3-angelate) are sufficient for enduring regression of skin cancer lesions (including melanoma) in preclinical models [14,15].”
BackgroundSelf-citationRobertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K., Cruz, J. C., Goldberg, S. L., Musib, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3146 · Cited by 232 · cited 1×
“For example, enzastaurin, an orally available specific inhibitor of PKC-b, showed limited efficacy as a single agent in Phase II studies of advanced diffuse large B-cell lymphoma or non-small cell lung cancer [10,11].”
Background
Cited by
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270
“A study by Boyle and co-workers [236] tested whether intra-lesional injection of a PKC-activating diterpene ester would affect the tumor growth in intact mice.”
BackgroundDiagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors
Nardi, A. B. D., Horta, R. D. S., Fonseca‐Alves, C. E., de Paiva, F. N., Linhares, L. C. M., Firmo, B. F., Sueiro, F. A. R., de Oliveira, K. D., Lourenço, S. V., Strefezzi, R. D. F., et al. (2022) · Cells · doi:10.3390/cells11040618 · Cited by 141
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“Recent advancements in cancer treatment strategies have explored the modulation of PKC signaling, utilizing activators like Bryostatins (103) and Epoxytiglianes (104 – 106), as well as inhibitors such as CGP 41251, to counteract tumor growth and reverse multidrug resistance (107).”
Background
Metadata
- Authors
- Boyle, G. M., D'Souza, M. M. A., Pierce, C. J., Adams, R. A., Cantor, A. S., Johns, J. P., Maslovskaya, L., Gordon, V. A., Reddell, P. W., & Parsons, P. G.
- Affiliations
- QIMR Berghofer Medical Research Institute (AU)
- The University of Queensland (AU)
- Corresponding author
- Boyle, Glen M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-10-01
- Volume
- 9
- Issue
- 10
- Pages
- e108887
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4182759
- OpenAlex
- W1992030745
- Cited by
- 101
- References
- 34
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 14 · 2020: 13 · 2019: 9 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 6 · 2014: 1
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- University of Queensland
- Queensland Government
- Qbiotics
- Medical Research Council
- National Health and Medical Research Council (1017676)
- Topics
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- protein kinase C activators, intralesional chemotherapy, skin cancer, tumor ablation, diterpene esters, PKC isoforms, phorbol myristate acetate, respiratory burst, hemorrhagic necrosis, tumor vascular permeability, eschar formation, cancer cell death, pharmacokinetics
- MeSH terms
- Animals, Antineoplastic Agents, Diterpenes, Humans, Indoles, Maleimides, Neoplasms, Protein Kinase C, Injections, Intralesional, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models. https://app.cochat.ai/papers/10.1371/journal.pone.0108887
- The paper
- Boyle, G. M., D'Souza, M. M. A., Pierce, C. J., Adams, R. A., Cantor, A. S., Johns, J. P., Maslovskaya, L., Gordon, V. A., Reddell, P. W., & Parsons, P. G. (2014). Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models. PLoS ONE. https://doi.org/10.1371/journal.pone.0108887
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.